Drugs / CE1226
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT07326592 | Jul 2026 → Sep 2033 expected | alpha 1-antitrypsin deficiency, pulmonary emphysema | CSL Behring | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CE1226 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07326592 ↗ |
| Modality | Protein / enzyme biologic | “Human alpha1-proteinase inhibitor” NCT07326592 ↗ |
| Route | Intravenous | “administered via intravenous (IV) infusion weekly over 3 years” NCT07326592 ↗ |